Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome

Dravet syndrome is a rare, severe, treatment-resistant developmental epileptic encephalopathy with onset in the first year of life in otherwise normal infants. The syndrome is characterized initially by heat- or fever-triggered hemi-clonic and generalized convulsive seizures, often prolonged, during the first year of life, with subsequent development of other seizure types [1, 2]. In addition to high seizure burden, children with Dravet syndrome often develop comorbidities, including motor and speech impairment, learning disabilities, and behavioral problems, including autism, and have a decreased quality of life [2, 3].

0